Phase 2Recruiting
Small Trial of Alendronate Impact on the Reservoir of HIV (STAIR-HIV)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
- Enrolment
- 30 planned
- Conditions
- HIV
- Interventions
- Alendronate; Placebo
- Ages
- adults, older adults
- Registry
- NCT07216794
From the registry
This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.
Primary outcomes
- Change in intact HIV-1 deoxyribonucleic acid (DNA) copies by the Intact Proviral DNA Assay (IPDA) in peripheral blood